How common are Mounjaro side effects?

Q: Is Mounjaro better than Ozempic?

In head-to-head trial data, tirzepatide (Mounjaro) produced greater weight loss than semaglutide (Ozempic): approximately 20-22% vs. 14-15% body weight reduction. Mounjaro works on two receptors (GLP-1 and GIP) compared to Ozempic's one (GLP-1 only). Both are weekly injections at similar price point

Q: What happens if you stop taking Mounjaro?

Like other GLP-1/GIP receptor agonists, stopping Mounjaro typically leads to weight regain. Clinical trial extension data shows that patients who discontinued tirzepatide regained a substantial portion of lost weight within 12 months, as the appetite-suppressing and gastric-slowing effects disappear

Direct Answer

Mounjaro (tirzepatide) shares a similar side effect profile with Ozempic. Nausea is the most common (12-18%), followed by diarrhea (12-17%), decreased appetite (5-11%), vomiting (5-9%), and constipation (6%). These GI effects are most pronounced during dose escalation and generally improve over time. Serious side effects are rare but include pancreatitis and gallbladder events. Like all GLP-1 agonists, Mounjaro carries a boxed warning about thyroid C-cell tumors observed in rodent studies, though this has not been confirmed in humans.

Based on published clinical trial data and FDA prescribing information. This is not medical advice — always consult your healthcare provider.

Supporting Evidence

Side Effects

Nausea31–36%

Diarrhea20–23%

Vomiting13–16%

Constipation17–19%

Decreased appetite40%+

Serious (rare)

Pancreatitis (<1%) — discontinue and do not restart if confirmed
Gallbladder disease / gallstones (rapid weight loss increases risk)
Kidney injury (from dehydration, not direct nephrotoxicity)

FDA Black Box Warning

THYROID C-CELL TUMORS

Tirzepatide causes dose-dependent thyroid C-cell tumors in rodents. Human relevance is unknown. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.

Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Clinical Trials

Expected HbA1c reduction: −1.87% to −2.46% from baseline (SURPASS-1, 5–15mg). SURPASS-2: tirzepatide superior to semaglutide 1mg for HbA1c. SURMOUNT-1: −22.5% body weight at 72 weeks (15mg). SURMOUNT-4: full weight regain within 1 year of stopping — documented in the withdrawal arm.

SURPASS-1 (Lilly)SURPASS-2 (Lilly)SURPASS-3 (Lilly)

Funding transparency: All SURPASS and SURMOUNT trials were designed, funded, and controlled by Eli Lilly. Lilly reported $5.8B in tirzepatide revenue in 2024 alone — its fastest product ramp in history. Lead investigators … See full funding details

Read the complete Mounjaro® / Zepbound® guide

Side effect rates, clinical trial data, funding transparency, drug interactions, tapering protocols, and lifestyle alternatives — all in one place.

View Mounjaro® / Zepbound®